Steven Nissen, ACC 2022: Results of the APOLLO trial
touchCARDIO spoke to Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) to discuss his presentation at the American College of Cardiology Annual Meeting 2022, providing the results of the APOLLO trial, a placebo-controlled double-blind dose-ranging trial assessing the magnitude and duration of effects of a short-interfering RNA targeting lipoprotein(a).
1. Could you give us a brief overview of short interfering ribonucleic acid therapeutics and their clinical potential? 00:12-00:50
2. What are the unmet needs in cardiovascular risk reduction in people with high levels of lipoprotein(a)? 00:50-01:41
3. What are the aims and design of the APOLLO study? 01:41-02:33
4. What have been the findings of the study to date? 02:33-04:58
5. What will be the next steps in the clinical development of SLN360? 04:58-05:48
Speaker Disclosure: Steven Nissen reports that the Cleveland Clinic Center for Clinical Research has received funding to perform clinical trials from Abbvie, AstraZeneca, Amgen, Bristol Myers Squibb, Cerenis, Eli Lilly, Esperion, Medtronic, MyoKardia, Novartis, Pfizer, The Medicines Company, Silence Therapeutics, Takeda and Orexigen. Steven Nissen is involved in these clinical trials, but receives no personal remuneration for his participation. Steven Nissen consults for many pharmaceutical companies, but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
Share this Video
Related Videos In Cardiovascular Disease
John Forrest, ACC 2023: Evolut low risk trial, transcatheter versus surgical aortic valve replacement in patients at low surgical risk
The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to discuss the eligibility criteria, the key findings and the outlook for […]
John Forrest, ACC 2023: The treatment paradigm for patients with aortic stenosis
The treatment paradigm for aortic stenosis has developed dramatically in the past decade. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to outline and discuss the developments. Dr Forrest presented an abstract entitled ‘Transcatheter Versus Surgical Aortic Valve Replacement In Aortic Stenosis Patients […]
Steven Nissen, ACC 2023: Lipid-lowering therapies – current and future options
Many lipid-lowering therapies exist, such as statins to manage and reduce lipid levels. While statins are the most commonly used medication, some patients may need additional interventions to lower their LDL cholesterol levels. In this touchCARDIO interview, we speak with Prof. Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) to explore current and developing novel lipid-lowering […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!